First Phase 3 study of TNX-103 in PH-HFpEF patients to start in 4Q 2023 (The LEVEL Study)FDA agreement that 6MWD...
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA) will host its Investor Day today beginning at 8:00 a.m. CT. A team of...
On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial...
REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on...
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI®(sparsentan) in IgAN and Phase 3 DUPLEX Study...
Company to Discuss Upcoming Briquilimab Clinical Studies in Both Chronic Spontaneous Urticaria and Chronic Inducible UrticariaREDWOOD CITY, Calif., Oct. 09,...
First Patient Expected to be Dosed by Year-end 2023; Early Data Expected by Mid-2024 Clinical Study in Chronic Inducible Urticaria...
Goodness Growth and Grown Rogue each issued warrants to the other to purchase listed shares Issuances were announced in May...
LONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”),...
New results support the neuroprotective effects of ATH-1105 in preclinical models of ALS, as indicated by consistent reduction in plasma...
mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccinesCompany...
DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two...
Provides Initial $59 Million and up to $168 Million Contingent on MilestonesNATICK, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ModeX...
Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million1, and long-term deposit at €9.3 million2, as of...
AUDUBON, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced...
TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed...
All three Fanconi Anemia patients treated with briquilimab achieved full donor engraftment and full blood count recoveryBriquilimab was well tolerated...
FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) and eGFR chronic...
Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALLPALO ALTO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) --...
